 GH Research PLC NASDAQ: GHRS has reported the outcome of the Phase 2 part of a Phase 12 trial of GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression TRD. The trial met its primary endpoint with 7 of 8 patients 87.5 in remission at day 7 after dosing. 